Genprex
(NASDAQ: GNPX), a clinical stage gene therapy company developing a new and
potentially life-saving approach to treating some of the world’s most deadly
cancers based upon a novel proprietary technology platform, today announced its
entry into securities purchase agreements with institutional investors for the
purchase and sale of 7,620,000 shares of common stock. According to the update,
the offering is priced at-the-market under Nasdaq rules with par value $0.001
per share at an offering price of $1.05 per share, pursuant to a registered
direct offering. Gross proceeds will be approximately $8,000,000 before
deducting fees and other estimated offering expenses, and the company intends
to use the net proceeds to advance its lead clinical programs in non-small cell
lung cancer (“NSCLC”) and for working capital and general corporate purposes.
Closing of the registered direct offering is expected to occur on or about
January 27, 2020, subject to the satisfaction of customary closing conditions.
To view the full press release, visit http://ibn.fm/L5l9n
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for cancer patients based
upon a unique proprietary technology platform. Genprex’s platform technologies
are designed to administer cancer-fighting genes by encapsulating them into
nanoscale hollow spheres called nanovesicles, which are then administered
intravenously and taken up by tumor cells where they express proteins that are
missing or found in low quantities. The company’s lead product candidate,
Oncoprex(TM) immunogene therapy for non-small cell lung cancer (“NSCLC”), has a
multimodal mechanism of action whereby it interrupts cell signaling pathways
that cause replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells, and
modulates the immune response against cancer cells. Oncoprex has also been
shown to block mechanisms that create drug resistance. For more information,
please visit the company’s web site at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
